Global Human Microbiome Market is expected to foresee significant growth. APAC to lead the growth!
- Himanshu Patni
- November 21, 2022
- Human Microbiome Market, Human Microbiome Market Growth, Human Microbiome Market Share, Human Microbiome Market Size
- 0 Comments
Human microbiome consists of various microorganisms, including archaea, viruses, bacteria, and eukaryotes which reside within or outside the human body. These microorganisms have been shown to have a significant impact on human physiology, and therefore play a critical role in metabolic and immune functions. In the last decade, microbiome therapy has gained enormous attention from the government as well as private organizations. For instance, from 2007-2016, the National Institute of Health (NIH) invested USD 215 million in the Human Microbiome Project (HMP) and USD 728 million in extramural human microbiome research activities. Apart from this, Horizon 2020 is one of the biggest European Union research and innovation programs which received funding of USD 96.9 million available for seven years (2014-2020).
The Human Microbiome Market is expected to grow at a steady rate of around 26.7% during the forecast period (2022-2028) owing to a surge in the incidence of lifestyle disorders, rising expenditure on research and development activities, and the increase in funding by the federal government. Apart from this, the rapid increase in investment from the pharmaceutical giants, technological advancements, and its role in the management of chronic diseases is also propelling the market’s growth during the forecast period. In the past few years, there have been increasing trends among strategies such as collaboration and agreement among companies for market growth.
Based on product type, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs, medical foods, supplements, and others. The drugs segment is expected to grow with high CAGR rates during the forecast period which is mainly attributed to the rising number of human microbiome-based therapeutic products in clinical trials along with increased funding to develop microbiome-based medications. For instance, in November 2022, the Therapeutic Goods Administration (TGA) approved BiomeBank’s product for the restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection (C.difficile).
Based on application, the market is categorized into diagnostics and therapeutics. The therapeutics segment held the dominant share in the global market due to increased funding in research and development for microbiome-based therapies, technological advancements, and an increase in the prevalence of chronic diseases.
For a detailed analysis of the Global Human Microbiome Market browse through – https://univdatos.com/report/human-microbiome-market/
Based on the disease, the human microbiome market is segmented into obesity, infectious diseases, cancer, autoimmune diseases, metabolic & gastrointestinal disorders, and others. The infectious disease segment is expected to witness high CAGR rates during the forecast period. The surge in the incidence of infections due to microbial dysbiosis, as a result of antibiotic treatment, and the rising number of clinical trials for the development of target-specific microbiome-based therapies are the major factors propelling the growth of this segment during the forecast period.
Based on the distribution channel, the human microbiome market has been classified into retail pharmacies, hospital pharmacies, and online pharmacies. Online pharmacies are expected to grow with high growth rates which are attributed to the surge in mobile usage, high internet penetration, and an increase in the number of people conducting online transactions that have raised the demand for online drugs through app-based platforms in recent years. For instance, there were around 106 mobile cellular subscriptions (per 100 people) in 2020, all over the world.
Request for a sample of the report browse through – https://univdatos.com/get-a-free-sample-form-php/?product_id=28343
For a better understanding of the market adoption of the human microbiome industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period due to rise in government initiatives to enhance awareness, an increase in medical tourism, increasing research and development activities in the region, and a rise in the incidences of chronic diseases, autoimmune disorders, and lifestyle related disorders. For example, the 5th Microbiome R&D and Business Collaboration Congress were held in Taiwan, Asia in March 2019, the conference focused on recent developments in the gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome, and diet.
Some of the major players operating in the market include Enterome Biosciences SA, Yakult Honsha Co., 4D Pharma, Second Genome, Seres Therapeutics, Vedanta Biosciences, Inc., AOBiome, Microbiome Therapeutics LLC, and OptiBiotix HEALTH PLC.
Global Human Microbiome Market Segmentation
Market Insight, by Product Type
• Diagnostics Tests
• Medical Foods
Market Insight, by Application
Market Insight, by Disease
- Infectious Disease
- Autoimmune Diseases
- Metabolic & Gastrointestinal Disorders
Market Insight, by Distribution Channel
Market Insight, by Region
- North America
- Rest of North America
- United Kingdom
- Rest of Europe
- Rest of Asia-Pacific
- Rest of the World
Top Company Profiles
- Enterome Biosciences SA
- Yakult Honsha Co.
- 4D Pharma
- Vedanta Biosciences, Inc.
- Seres Therapeutics
- Metabiomics Corp.
- Microbiome Therapeutics LLC
- Second Genome
- OptiBiotix HEALTH PLC